Abstract At present, allogeneic hematopoietic stem cell transplantation is still the only way to cure chronic myelogenous leukemia. With the advances of HLA matching technology, application of tyrosine kinase inhibitors before and after transplantation, improvement of postoperative immune status and fusion gene monitoring, and the control of postoperative complications, especially graft-versus-host disease etc. allogeneic hematopoietic stem cell transplantation is displaying better efficacy in the treatment of chronic myelogenous leukemia, and the quality of life of patients has also been significantly improved. This article reviews the recent research advances on the allogeneic hematopoietic stem cell transplantation and related support technologies for treatment of chronic myeloid leukemia.
题目: 慢性髓系白血病异基因造血干细胞移植的研究进展.
摘要: 目前，异基因造血干细胞移植（allogeneic hematopoietic stem-cell transplantation，allo-HSCT）依旧是根治慢性髓系白血病（chronic myelogenous leukemia，CML）的唯一方法。随着HLA基因配型技术的改进、移植前后酪氨酸激酶抑制剂（tyrosine kinase inhibitor，TKI）的应用、术后免疫状态及融合基因监测的进步、术后并发症尤其是移植物抗宿主病（graft-versus-host disease，GVHD）的控制得到加强等，异基因造血干细胞移植在慢性粒细胞白血病治疗中正展现出更好的疗效，患者的生存质量也有了显著提高。本文将就近年来异基因造血干细胞移植及其相关支持技术在慢性髓系白血病治疗中最新研究进展作一综述。.